Register Login
Register to leave comments
  • News bot Oct. 24, 2025, 12:28 p.m.

    📋 GENPREX, INC. (GNPX) - Clinical Trial Update

    Filing Date: 2025-10-24

    Accepted: 2025-10-24 08:26:43

    Event Type: Clinical Trial Update

    Event Details:

    Genprex Inc. (GNPX) Announces Clinical Trial Update Genprex Inc. (GNPX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: exercise, agreements
    • Diseases/Conditions: full of short-term warrants AUSTIN
    • Collaboration: H.C. Wainwright & Co.
    • Updated Timeline: October 23, 2025, about October 24, 2025

    🔬 Clinical Development Pipeline (GENPREX, INC.):

    Product Type Development Stage Therapeutic Area Source
    Platinum-Based Chemotherapy DRUG Phase PHASE1 Carcinoma, Non-Small Cell Lung ClinicalTrials.gov
    quaratusugene ozeplasmid BIOLOGICAL Phase PHASE1 Carcinoma, Non-Small Cell Lung ClinicalTrials.gov
    osimertinib DRUG Phase PHASE1 Carcinoma, Non-Small Cell Lung ClinicalTrials.gov
    atezolizumab BIOLOGICAL Phase PHASE1 Small Cell Lung Cancer Extensive Stage ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Genprex Inc.
    • CIK: 0001595248
    • Ticker Symbol: GNPX
    • Period End Date: 2025-10-23
    • Document Type: 8-K

Search

News categories